WEKO3
アイテム
Dual targeting of PD-L1 and integrin for preclinical PET imaging of cancers
https://repo.qst.go.jp/records/77482
https://repo.qst.go.jp/records/77482550c6f45-c6b4-43b1-aa42-23df68591c0e
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2019-11-11 | |||||
| タイトル | ||||||
| タイトル | Dual targeting of PD-L1 and integrin for preclinical PET imaging of cancers | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Kuan, Hu
× Kuan, Hu× Kuan, Hu |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Molecular imaging is significant to personalized and precision medicine. Although singly targeted imaging probes are making a substantial impact both clinically and preclinically, molecular imaging strategies using bispecific probes have enabled improved visualization of cancer in recent years through synergistic targeting of two ligands.1 Dual targeting strategy can improve the imaging contrast by enhancing the specific uptake. Immune checkpoint PD-L1 is a prominent biomarker for patient selection in immune checkpoint therapy. Here, we aim to develop a bispecific probe for tumor imaging by combining an integrin-targeting peptide cycloRGD and a PD-L1-targeting peptide TPP-12. | |||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 第59回日本核医学会学術総会 | |||||
| 発表年月日 | ||||||
| 日付 | 2019-11-02 | |||||
| 日付タイプ | Issued | |||||
